RxElite Research Development from 2010 to 2026

RXEI Stock  USD 0.0001  0.00  0.000003%   
RxElite's Research Development is increasing with slightly volatile movements from year to year. Research Development is estimated to finish at about 3.8 M this year. For the period between 2010 and 2026, RxElite, Research Development quarterly trend regression had mean deviation of  355,819 and range of 3.8 M. View All Fundamentals
 
Research Development  
First Reported
2010-12-31
Previous Quarter
3.6 M
Current Value
3.8 M
Quarterly Volatility
801.9 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check RxElite financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among RxElite's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 5.6 M or Total Revenue of 2.4 M, as well as many indicators such as Price To Sales Ratio of 0.0077, Dividend Yield of 0.0 or PTB Ratio of 0.0039. RxElite financial statements analysis is a perfect complement when working with RxElite Valuation or Volatility modules.
  
Build AI portfolio with RxElite Stock
Check out the analysis of RxElite Correlation against competitors.
For more detail on how to invest in RxElite Stock please use our How to Invest in RxElite guide.

Latest RxElite's Research Development Growth Pattern

Below is the plot of the Research Development of RxElite over the last few years. It is RxElite's Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in RxElite's overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

RxElite Research Development Regression Statistics

Arithmetic Mean3,027,259
Geometric Mean2,121,547
Coefficient Of Variation26.49
Mean Deviation355,819
Median3,145,995
Standard Deviation801,907
Sample Variance643.1B
Range3.8M
R-Value0.52
Mean Square Error500.7B
R-Squared0.27
Significance0.03
Slope82,528
Total Sum of Squares10.3T

RxElite Research Development History

20263.8 M
20253.6 M
20113.1 M
2010 2795.0

About RxElite Financial Statements

Investors use fundamental indicators, such as RxElite's Research Development, to determine how well the company is positioned to perform in the future. Although RxElite's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Research Development3.6 M3.8 M

Currently Active Assets on Macroaxis

When determining whether RxElite offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of RxElite's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rxelite Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rxelite Stock:
Check out the analysis of RxElite Correlation against competitors.
For more detail on how to invest in RxElite Stock please use our How to Invest in RxElite guide.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of RxElite. If investors know RxElite will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about RxElite listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.03)
Revenue Per Share
0.096
Quarterly Revenue Growth
3.321
Return On Assets
(0.38)
Return On Equity
(2.94)
The market value of RxElite is measured differently than its book value, which is the value of RxElite that is recorded on the company's balance sheet. Investors also form their own opinion of RxElite's value that differs from its market value or its book value, called intrinsic value, which is RxElite's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because RxElite's market value can be influenced by many factors that don't directly affect RxElite's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between RxElite's value and its price as these two are different measures arrived at by different means. Investors typically determine if RxElite is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, RxElite's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.